Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Thatcher

Showing results (101-110 of 289) with videos related to

Pageof 29
Sort By:
Cancer|September 15, 1982
Intermittent high-dose cyclophosphamide with and without prednisolone: a study of the relationships between toxicity, response and survival in metastatic lung cancerN Thatcher, J Wagstaff, P Wilkinson, et al.
Cancer|June 1, 1986
Treatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiationN Thatcher, H Anderson, R James, et al.
Seminars in Oncology|June 1, 1997
Gemcitabine: symptomatic benefit in advanced non-small cell lung cancerN Thatcher, G Jayson, B Bradley, et al.
Cancer|January 15, 1981
Malignant melanoma in children and adolescentsC B Pratt, M K Palmer, N Thatcher, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1983
Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinomaP M Wilkinson, P A O'Neill, N Thatcher, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1996
Increasing the dose intensity of chemotherapy by means of granulocyte-colony stimulating factor (G-CSF) support in the treatment of small cell lung cancer (SCLC)D J Girling, N Thatcher, P I Clark, et al.
British Journal of Cancer|February 24, 2005
Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy--a longitudinal studyM N Harvie, A Howell, N Thatcher, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1991
A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancerH Anderson, J Prendiville, N Thatcher, et al.
Seminars in Oncology|August 1, 1997
Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration scheduleM R Ranson, G Jayson, S Perkins, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1995
Chemotherapy in non-small cell lung cancerN Thatcher, M Ranson, S M Lee, et al.
Pageof 29

Showing results (101-110 of 289) with videos related to

Sort By:
Pageof 29
Cancer|September 15, 1982
Intermittent high-dose cyclophosphamide with and without prednisolone: a study of the relationships between toxicity, response and survival in metastatic lung cancerN Thatcher, J Wagstaff, P Wilkinson, et al.
Cancer|June 1, 1986
Treatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiationN Thatcher, H Anderson, R James, et al.
Seminars in Oncology|June 1, 1997
Gemcitabine: symptomatic benefit in advanced non-small cell lung cancerN Thatcher, G Jayson, B Bradley, et al.
Cancer|January 15, 1981
Malignant melanoma in children and adolescentsC B Pratt, M K Palmer, N Thatcher, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1983
Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinomaP M Wilkinson, P A O'Neill, N Thatcher, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1996
Increasing the dose intensity of chemotherapy by means of granulocyte-colony stimulating factor (G-CSF) support in the treatment of small cell lung cancer (SCLC)D J Girling, N Thatcher, P I Clark, et al.
British Journal of Cancer|February 24, 2005
Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy--a longitudinal studyM N Harvie, A Howell, N Thatcher, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1991
A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancerH Anderson, J Prendiville, N Thatcher, et al.
Seminars in Oncology|August 1, 1997
Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration scheduleM R Ranson, G Jayson, S Perkins, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1995
Chemotherapy in non-small cell lung cancerN Thatcher, M Ranson, S M Lee, et al.
Pageof 29